Due to Covid restrictions the office is closed, if you have an urgent query please contact: firstname.lastname@example.org
GermErase launches to give confidence to UK businesses and hospitals
First British commercial product to be tested on live SARS-Cov-2, the virus causing COVID-19
Multi-surface protector kills up to 99.9999% of pathogens in under 30 seconds and provides a protective barrier for up to 48 hours
British scientific breakthrough can turn the tide against hospital infections and superbugs, while supporting vaccines in the fight against COVID-19 and saving the NHS billions
GermErase, a new brand at the frontline of protecting against COVID-19, infections and superbugs, has launched its first product range.
Available as a cleaning spray and a hand spray with wipes, with aerosols and hand wash to follow, GermErase is a unique formulation that kills up to 99.9999% of pathogens, including the virus that causes COVID-19, in under 30 seconds – faster and more effective than the next best product. It bonds to surfaces to provide total protection without any reduction in performance for up to 48 hours and remains effective for 28 days.
GermErase has been tested to global standards in independent facilities at the University of Southampton, including on live strains of SARS-Cov-2. The British business has invested £1m in testing the product.
As 99.9% water, GermErase is safe and has low toxicity, meaning it does not irritate skin in the way alcohol gels can and, unlike alcohol gels, is not flammable. It uses common ingredients that have already been approved for medical and cleaning purposes and is ready to distribute at scale across the country via specialist cleaning supplier, Denis Rawlins Ltd.
Professor Bill Keevil, Professor of Environmental Healthcare at the University of Southampton, comments, “An invention like this does not come across your desk very often. We have found that GermErase demonstrates remarkable breadth of efficacy against bacteria and viruses, speed of kill, residual efficacy and shows no evidence of antimicrobial resistance.”
GermErase is more effective than alcohol gel and, alongside vaccines, can help to turn the tide against COVID-19 and a broad spectrum of other dangerous pathogens. While alcohol gels and sanitisers – products recommended by the World Health Organisation – are dependent on concentration levels and a lengthy period of application, GermErase is easy to use and completely kills the virus within seconds with a simple spray.
The products can be used by medical professionals in hospitals but are also quick and easy to use by private sector businesses – giving employers and employees the confidence to return to work safely and unlock the economic recovery in the UK. GermErase will launch a consumer product range for the general public in Spring 2021.
The urgency of antibiotic resistance is well known among the medical community and increasingly by wider society. GermErase provides a defence by preventing infection, instead of relying on the development of new cures and antibiotics.
Inspired by the most human of stories, GermErase was invented by Rob Scoones, a former retail business owner. After losing someone very close to him, Rob dedicated his life to eradicating the superbug crisis in our hospitals and worldwide. Through the relentless pursuit of this vision, Rob developed the GermErase product, combining common ingredients in a way that has delivered remarkable efficacy against all known pathogens, including SARS-Cov-2.
It has been estimated that a 10% reduction in infections and superbugs in hospitals would save the NHS £1bn annually. GermErase can kill and protect against all known infections and superbugs and is available to use throughout healthcare facilities immediately.
Matthew Higdon, Chairman of GermErase, comments, “Our intention is for GermErase to become the first line of defence against infection for hospitals, businesses and families across the country. This product will allow us to get our freedom back and live with peace of mind that we are protected against pathogens like Coronavirus. Our ambition is for this British breakthrough to represent a landmark moment in the fightback against COVID-19, infections and superbugs.”